following an abbreviated submission:
etravirine (Intelence®) is accepted for restricted use within NHS Scotland.
Indication under review: in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.
SMC restriction: to be prescribed under the supervision of specialists in paediatric HIV.
SMC has previously accepted etravirine for use in combination with a boosted protease inhibitor and other antiretroviral medicinal products for the treatment of HIV-1 infection in antiretroviral treatment experienced adult patients. Etravirine is listed in the British National Formulary for Children 2012-2013 for the treatment of HIV infection.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- etravirine (Intelence)
- SMC ID:
- 901/13
- Indication:
- In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 09 September 2013